Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL22265262 | 0.99 | KCNH2 (0.43) | KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL514444 | 0.99 | KCNH2 (0.43) | KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL318766 | 0.99 | KCNH2 (0.43) | KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL318565 | 0.99 | KCNH2 (0.43) | KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL318763 | 0.99 | KCNH2 (0.43) | KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL1331128 | 0.99 | KCNH2 (0.43) | KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL318174 | 0.99 | KCNH2 (0.43) | KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL192398 | 0.96 | ACHE (0.40) | KCNH2ACHEALDH1A1MAPTHTT | |
| Trifluoromethanesulfonic Acid SCHEMBL1293509 | 0.95 | KCNH2 (0.40) | KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL28555818 | 0.94 | ACHE (0.40) | KCNH2ACHEALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY INC (US) | 2021-12-23 | — | — | US | claimed |
| US-20130341561-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY, INC. (US) | 2013-12-26 | — | — | US | claimed |
| US-7718579-B2 | Electrochemical deblocking using a hydrazine derivative | COMBIMATRIX CORPORATION (US) | 2010-05-18 | — | — | US | claimed |
| EP-1869061-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | Combimatrix Corporation (US) | 2007-12-26 | — | — | EP | claimed |
| EP-1805206-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | Combimatrix Corporation (US) | 2007-07-11 | — | — | EP | claimed |
| US-20070034513-A1 | Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array | COMBIMATRIX CORPORATION | 2007-02-15 | — | — | US | claimed |
| WO-2007006418-A1 | IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-01-18 | — | — | WO | claimed |
| WO-2006131234-A1 | COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-12-14 | — | — | WO | claimed |
| WO-2006105037-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | COMBIMATRIX CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| WO-2006031814-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | COMBIMATRIX CORPORATION (US) | 2006-03-23 | — | — | WO | claimed |
| US-20060054511-A1 | Electrochemical deblocking using a hydrazine derivative | CUSTOMARRAY, INC. | 2006-03-16 | — | — | US | claimed |
| WO-2024189058-A1 | LITHIUM-ION BATTERY | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-09-19 | — | — | WO | disclosed |
| EP-4432395-A1 | LITHIUM-ION BATTERY | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-09-18 | — | — | EP | disclosed |
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY INC (US) | 2021-12-23 | — | — | US | disclosed |
| WO-2020152206-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-07-30 | — | — | WO | disclosed |
| EP-1805206-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | Combimatrix Corporation (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070034513-A1 | Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array | COMBIMATRIX CORPORATION | 2007-02-15 | — | — | US | disclosed |
| WO-2007006418-A1 | IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006031814-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | COMBIMATRIX CORPORATION (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060054511-A1 | Electrochemical deblocking using a hydrazine derivative | CUSTOMARRAY, INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | DNMT1, DNASE1, DNPEP | KCNH2 484/4885ACHE 701/4885MEN1 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.